News und Analysen
![LivaNova Announces Proposed Private Offering of $250 Million of Cash Exchangeable Senior Notes](/assets/news/news1-f26f2455ece0c3cbea64441818e795358cadddddb27e796f883ae2bd06f66139.png)
LivaNova Announces Proposed Private Offering of $250 Million of Cash Exchangeable Senior Notes
LivaNova PLC (NASDAQ:LIVN) ("LivaNova") today announced its intention to offer $250 million aggregate principal amount of cash exchangeable senior notes due 2025 through its wholly owned U.S
![LivaNova to Present at the Jefferies Virtual Healthcare Conference](/assets/news/news10-be520e400538f920c1970757e43cd0aa35625c1095be243829bb7a152346bd95.png)
LivaNova to Present at the Jefferies Virtual Healthcare Conference
LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today announced Thad Huston, Chief Financial Officer, will present at the Jefferies Virtual Healthcare Conference on
![New Data on LivaNova Perceval Sutureless Aortic Valve Show Consistent Outcomes, Lower Procedure Times Compared to Sutured Valves](/assets/news/news11-1ebbf8540812dc8f080ecfeb67ce19c492651a7c439bd800cec2630c3a04a840.png)
New Data on LivaNova Perceval Sutureless Aortic Valve Show Consistent Outcomes, Lower Procedure Times Compared to Sutured Valves
LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, presented the first data from the Perceval® Sutureless Implant Versus Standard-Aortic Valve Replacement
![New Study Shows Significant Positive Impact of Vagus Nerve Stimulation Therapy for Patients with Treatment-Resistant Bipolar Depression](/assets/news/news2-a19c21d90ec8043c932052617f43da76ea8e48ecd096318e237ea24d69a5c8b8.png)
New Study Shows Significant Positive Impact of Vagus Nerve Stimulation Therapy for Patients with Treatment-Resistant Bipolar Depression
LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today announced the publication of a new study in the International Journal of Bipolar Disorders1 that showed
![LivaNova to Present PERSIST-AVR Findings at American Association for Thoracic Surgery 100th Annual Meeting](/assets/news/news8-29d1d55c755b03e328399113b5bdd004223f995e95194ba5ee80af9da39a41e3.png)
LivaNova to Present PERSIST-AVR Findings at American Association for Thoracic Surgery 100th Annual Meeting
LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, will present new findings from its Perceval® Sutureless Implant Versus Standard-Aortic Valve Replacement
![LivaNova to Present at the UBS Virtual Global Healthcare Conference](/assets/news/news14-e52b56a6adda780de8ab40d75cabe14dcfa77fc9676e986401297a29e68c991e.png)
LivaNova to Present at the UBS Virtual Global Healthcare Conference
LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today announced Damien McDonald, Chief Executive Officer, will present at the UBS Virtual Global Healthcare Conference on
![LivaNova Reports First Quarter 2020 Results](/assets/news/news13-125fa69a38b6955d740c18f7e750c42a3317f6873eded3044187d2ece3aa0ac7.png)
LivaNova Reports First Quarter 2020 Results
LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today reported results for the quarter ended March 31, 2020.
For the first quarter of 2020, worldwide sales
![LivaNova Bi-Flow-Kanüle erhält CE-Zeichen für ECMO-Anwendungen](/assets/news/news13-125fa69a38b6955d740c18f7e750c42a3317f6873eded3044187d2ece3aa0ac7.png)
LivaNova Bi-Flow-Kanüle erhält CE-Zeichen für ECMO-Anwendungen
LivaNova PLC (NASDAQ:LIVN), ein marktführendes Unternehmen für Medizintechnik und Innovationen, gab heute bekannt, dass seine Bi-Flow-Kanüle für extrakorporale Membranoxygenierung (ECMO) die
![LivaNova Bi-Flow Cannula Receives CE Mark for ECMO Applications](/assets/news/news6-ad07925a95156ae03dbe17caf44a9dc29f254ff2c2a42c7678d35288ad55cec8.png)
LivaNova Bi-Flow Cannula Receives CE Mark for ECMO Applications
LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today announced its Bi-Flow Extracorporeal Membrane Oxygenation (ECMO) cannula earned CE Mark approval for
![GSK Presents New Data from the GARNET Study Demonstrating Potential of Dostarlimab to Treat a Subset of Women with Recurrent or Advanced Endometrial Cancer](/assets/news/news18-f135f6c168ef56d2b112890081403b0a310104acfadbf4a8f72634bd390e98ac.png)
GSK Presents New Data from the GARNET Study Demonstrating Potential of Dostarlimab to Treat a Subset of Women with Recurrent or Advanced Endometrial Cancer
GlaxoSmithKline plc (LSE/NYSE:GSK) today announced data from an updated analysis of the GARNET trial, which demonstrated that dostarlimab, an investigational anti-programmed death-1 (PD-1)
![GSK Presents New Data from the GARNET Study Demonstrating Potential of Dostarlimab to Treat a Subset of Women with Recurrent or Advanced Endometrial Cancer](/assets/news/news18-f135f6c168ef56d2b112890081403b0a310104acfadbf4a8f72634bd390e98ac.png)
GSK Presents New Data from the GARNET Study Demonstrating Potential of Dostarlimab to Treat a Subset of Women with Recurrent or Advanced Endometrial Cancer
GlaxoSmithKline plc (LSE/NYSE:GSK) today announced data from an updated analysis of the GARNET trial, which demonstrated that dostarlimab, an investigational anti-programmed death-1 (PD-1)
![LivaNova Permitted to Modify Cardiopulmonary Products' Indications for Use to Include ECMO Therapy Beyond Six Hours to Address COVID-19](/assets/news/news14-e52b56a6adda780de8ab40d75cabe14dcfa77fc9676e986401297a29e68c991e.png)
LivaNova Permitted to Modify Cardiopulmonary Products' Indications for Use to Include ECMO Therapy Beyond Six Hours to Address COVID-19
LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today announced that several of its cardiopulmonary products are now permitted to be used in the U.S. for
![LivaNova to Host Conference Call for First Quarter 2020 Results](/assets/news/news1-f26f2455ece0c3cbea64441818e795358cadddddb27e796f883ae2bd06f66139.png)
LivaNova to Host Conference Call for First Quarter 2020 Results
LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, will host a conference call to discuss its first quarter 2020 results on Wednesday, April 29, 2020 at 1 p.m
![LivaNova Autonomic Regulation Therapy for Heart Failure Findings to be Presented at American College of Cardiology and World Congress of Cardiology Virtual Meeting](/assets/news/news8-29d1d55c755b03e328399113b5bdd004223f995e95194ba5ee80af9da39a41e3.png)
LivaNova Autonomic Regulation Therapy for Heart Failure Findings to be Presented at American College of Cardiology and World Congress of Cardiology Virtual Meeting
LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today announced two abstracts focused on implantable neuromodulation technology for patients with heart
![Symmetry, das LivaNova VNS Therapy-System für schwer zu behandelnde Depressionen, erhält CE-Prüfzeichen](/assets/news/news8-29d1d55c755b03e328399113b5bdd004223f995e95194ba5ee80af9da39a41e3.png)
Symmetry, das LivaNova VNS Therapy-System für schwer zu behandelnde Depressionen, erhält CE-Prüfzeichen
LivaNova PLC (NASDAQ:LIVN), ein marktführendes medizintechnisches Innovationsunternehmen, gab heute bekannt, dass sein System Vagus Nerve Stimulation Therapy® (VNS Therapy) Symmetry™ die
![LivaNova VNS Therapy System, Symmetry, Granted CE Mark for Difficult-to-Treat Depression](/assets/news/news16-82a218458f0e15ae617f9186b258dfd3add112716106c6ee3cbb48563ccdef52.png)
LivaNova VNS Therapy System, Symmetry, Granted CE Mark for Difficult-to-Treat Depression
LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today announced its Vagus Nerve Stimulation Therapy® (VNS Therapy) System, Symmetry™, earned CE Mark approval
![LivaNova Enters Research Collaboration with Verily to Gain New Insights into Vagus Nerve Stimulation Impact on Difficult-to-Treat Depression](/assets/news/news19-14feaf1b3ac689101974b5354f2ab8bb5cb2e7cb49a06b120b8491e9ebba31f4.png)
LivaNova Enters Research Collaboration with Verily to Gain New Insights into Vagus Nerve Stimulation Impact on Difficult-to-Treat Depression
LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today announced a research collaboration with Verily, an Alphabet company, to capture measures of depression
![LivaNova Reports Fourth Quarter and Full-Year 2019 Results](/assets/news/news4-fce0efe65d8ba787508ef718c0a20bed51e468dbc656c188c43e13f15b4a4f53.png)
LivaNova Reports Fourth Quarter and Full-Year 2019 Results
LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today reported results for the quarter and full-year ended December 31, 2019.
For the fourth quarter of
![LivaNova Receives FDA Clearance for 3T Heater-Cooler Device Modification](/assets/news/news6-ad07925a95156ae03dbe17caf44a9dc29f254ff2c2a42c7678d35288ad55cec8.png)
LivaNova Receives FDA Clearance for 3T Heater-Cooler Device Modification
LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today announced it received U.S. Food and Drug Administration (FDA) 510(k) clearance for a device
![New International Consensus Statement Proposes “Difficult-to-treat Depression” as a More Clinically Useful Definition than “Treatment-Resistant Depression”](/assets/news/news6-ad07925a95156ae03dbe17caf44a9dc29f254ff2c2a42c7678d35288ad55cec8.png)
New International Consensus Statement Proposes “Difficult-to-treat Depression” as a More Clinically Useful Definition than “Treatment-Resistant Depression”
LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, commends the recent international consensus statement published in the Journal of Affective Disorders for
![LivaNova to Host Conference Call for Fourth Quarter and Full-Year 2019 Results](/assets/news/news13-125fa69a38b6955d740c18f7e750c42a3317f6873eded3044187d2ece3aa0ac7.png)
LivaNova to Host Conference Call for Fourth Quarter and Full-Year 2019 Results
LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, will host a conference call to discuss its fourth quarter and full-year 2019 results on Wednesday, Feb. 26
![Eine neu veröffentlichte multizentrische RCT zeigt, dass Smith+Nephew PICO◊ sNPWT kanisterlose Unterdruck-Wundtherapie herkömmlicher tNPWT bei der Reduzierung von Wundfläche, -tiefe und -volumen bei DFU und UCV überlegen ist](/assets/news/news12-a6c8e663da6f66e4f8b76885d84b91bc276bfd92fd8727e9ade1f1d9f4df9b67.png)
Eine neu veröffentlichte multizentrische RCT zeigt, dass Smith+Nephew PICO◊ sNPWT kanisterlose Unterdruck-Wundtherapie herkömmlicher tNPWT bei der Reduzierung von Wundfläche, -tiefe und -volumen bei DFU und UCV überlegen ist
Smith+Nephew (LSE:SN, NYSE:SNN), das globale Medizintechnikunternehmen, freut sich, die Veröffentlichung von Ergebnissen aus einer neuen randomisierten kontrollierten klinischen Studie (RCT)
![Clinical trial demonstrated superior wound closure rates with PICO◊ compared to traditional NPWT in lower extremity ulcers1](/assets/news/news19-14feaf1b3ac689101974b5354f2ab8bb5cb2e7cb49a06b120b8491e9ebba31f4.png)
Clinical trial demonstrated superior wound closure rates with PICO◊ compared to traditional NPWT in lower extremity ulcers1
Smith+Nephew (LSE: SN, NYSE: SNN), the global medical technology business, today announces the publication of a new randomized controlled trial (RCT) which demonstrated that the use of PICO Single
![Amarin: Vorzeitige Bescherung durch die FDA!](/assets/news/news11-1ebbf8540812dc8f080ecfeb67ce19c492651a7c439bd800cec2630c3a04a840.png)
Amarin: Vorzeitige Bescherung durch die FDA!
Am vergangenen Freitag, dem 13. Dezember, war die Aktie von Amarin (WKN: A0NBNG) in den USA den größten Teil des Tages vom Handel ausgesetzt. Grund hierfür war eine bevorstehende, Kurs bewegende
![LivaNova to Present New Data on Vagus Nerve Stimulation Therapy System at the American Epilepsy Society 2019 Annual Meeting](/assets/news/news16-82a218458f0e15ae617f9186b258dfd3add112716106c6ee3cbb48563ccdef52.png)
LivaNova to Present New Data on Vagus Nerve Stimulation Therapy System at the American Epilepsy Society 2019 Annual Meeting
LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today announced it will present new registry data from two patient populations benefiting from Vagus Nerve